Clinical Significance of Elevated LDL Cholesterol

1. LDL as a Causal Agent for Atherosclerosis

2. The Atherogenic Mechanism

1. LDL enters the arterial intima and is oxidized (oxLDL) by reactive oxygen species (superoxide, hydrogen peroxide, nitric oxide).
2. oxLDL causes endothelial injury, triggering monocyte adhesion and migration into the subendothelium, where they become macrophages.
3. Macrophages ingest modified LDL via low-affinity, nonregulated scavenger receptors (unlike the regulated LDL receptor, these are not downregulated when cholesterol is sufficient), becoming lipid-laden foam cells.
4. Foam cells accumulate and release growth factors and cytokines, recruiting smooth muscle cells (SMCs) from the media into the intima, where they proliferate and produce collagen - forming the fibrous cap.
5. The lipid/necrotic core builds up as normal phagocytic processes are overwhelmed, forming a vulnerable plaque prone to rupture or erosion.

• Goldman-Cecil Medicine, 2-Volume Set and Lippincott's Biochemistry, 8th Ed

3. Small, Dense LDL - An Independent Risk Factor

• They are more susceptible to oxidation.
• They penetrate the vascular wall more readily.
• They upregulate endothelial adhesion molecules (ICAM-1, VCAM-1) and MCP-1.
• They activate macrophages via TLR-4 and the NF-κB inflammatory pathway.

4. Cardiovascular Risk by LDL Level

• Goldman-Cecil Medicine

5. Genetic Conditions: Familial Hypercholesterolemia (FH)

• Heterozygous FH affects ~1 in 250 persons worldwide. Caused by loss-of-function mutations in the LDLR gene (most common), PCSK9 gain-of-function mutations, or altered Apo B binding site mutations.
• Heterozygous FH causes premature coronary artery disease in men in their 30s-40s and women in their 40s-50s.
• Homozygous FH (1 in 500,000) manifests with ASCVD events in childhood and myocardial infarction by age 20.
• Goldman-Cecil Medicine and Robbins & Kumar Basic Pathology

6. Quantifying the Benefit of LDL Reduction

7. Indications for Treatment (2018 AHA/ACC Guideline)

1. Established clinical ASCVD
2. LDL-C > 190 mg/dL
3. Diabetes mellitus aged 40-75 years with high-risk features
4. 10-year ASCVD risk ≥ 7.5% (with risk-enhancing factors)

8. Treatment Hierarchy

Clinical Significance of Elevated LDL Cholesterol

Definition & Normal Values

Pathophysiology (Write This as a Flow)

• oxLDL is taken up by macrophages via scavenger receptors (non-regulated - do NOT switch off)
• Normal LDL receptors downregulate when cell has enough cholesterol - scavenger receptors do NOT
• Foam cells release cytokines → recruit smooth muscle cells → produce collagen (fibrous cap)
• Small, dense LDL is more atherogenic than large LDL (more easily oxidized, penetrates wall more)

Clinical Consequences of Elevated LDL

Genetic Condition: Familial Hypercholesterolemia (FH) (High-Yield)

Exam trap: In FH, LDL receptor is defective → hepatic LDL uptake reduced → blood LDL rises despite normal dietary intake.

Risk Quantification (Must-Know Numbers)

• LDL > 190 mg/dL → 5-fold higher lifetime ASCVD risk
• FH (untreated) → 20-fold higher lifetime ASCVD risk
• Every 39 mg/dL (1 mmol/L) reduction in LDL-C = 22% reduction in cardiovascular events
• Statin benefit is proportional to absolute LDL reduction

Treatment Ladder (Write in Order)

• Mechanism: Inhibit HMG-CoA reductase → less hepatic cholesterol → upregulate LDL receptors → more LDL cleared from blood
• Reduce LDL by 40-60%
• Drugs: Rosuvastatin 20-40 mg, Atorvastatin 40-80 mg

• Inhibits NPC1L1 in intestinal brush border → blocks cholesterol absorption
• Additional ~15-20% LDL reduction

• Block PCSK9 → prevent LDL receptor degradation → more receptors on hepatocytes → more LDL cleared
• Additional 50-60% LDL reduction on top of statin
• Used in FH, very high-risk patients, statin intolerance

• Interrupt enterohepatic bile acid recirculation → liver uses cholesterol to make more bile acids
• 15-25% reduction; contraindicated when TG > 300 mg/dL (can worsen hypertriglyceridemia)

AHA/ACC 2018 Guideline: 4 Groups for High-Intensity Statin

1. Clinical ASCVD (prior MI, stroke, PAD)
2. LDL-C ≥ 190 mg/dL
3. Diabetes mellitus, age 40-75 years
4. 10-year ASCVD risk ≥ 7.5% (calculated by Pooled Cohort Equations)

Secondary Causes of Elevated LDL (Always Exclude First)

Rule: Any LDL ≥ 160 mg/dL or TG ≥ 500 mg/dL → first rule out secondary causes before labeling primary.

One-Line Exam Answers

• Why does FH cause CAD early? - Loss of LDL receptors → no hepatic clearance → circulating LDL oxidizes and deposits in arteries
• Why are scavenger receptors dangerous? - They are not downregulated by intracellular cholesterol → unlimited foam cell formation
• Why can statins regress plaques? - Dramatic LDL reduction allows normal macrophage efferocytosis to clear necrotic debris and resolve inflammation
• Most atherogenic LDL subtype? - Small, dense LDL (sdLDL) - more oxidizable, penetrates endothelium more easily
• LDL reduction target in very high-risk patients? - < 55 mg/dL (European guidelines) or < 70 mg/dL (US guidelines) with ≥50% reduction